文献速递中毒与环境急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

铝暴露与人体毒性剂量-反应关系的系统评价

Dose-response relationships in aluminium toxicity in humans.
PubMed 文献 · Clin Toxicol (Phila) · 2022-02-18
一句话结论系统评价179例铝暴露者显示:透析液暴露的成人5期慢性肾病者铝神经毒性中位血铝467 µg/L,显著高于骨病142 µg/L和无症状过载35 µg/L(p<0.0001)。

本文为系统评价,检索1966年1月1日至2020年12月30日文献,纳入37篇论文、179例有个体数据的铝暴露者。暴露来源包括透析液(110例,中位暴露48个月)、口服氢氧化铝(20例,20个月)、血浆置换(16例,2个月)、婴儿配方奶粉(14例,最短2周)、膀胱内暴露(13例肿瘤患者,2天)及饮用水(6例)。透析液暴露成人中,铝神经毒性者中位血铝467 µg/L(IQR 230-752),显著高于骨病者142 µg/L(IQR 46-309)和无症状过载者35 µg/L(IQR 26-51)(均p<0.0001);膀胱内急性暴露13例全部出现铝神经毒性,中位血铝157 µg/L(IQR 45-276)。作者认为铝暴露可致神经毒性和骨病,尤其慢性肾病患者,并将这些浓度外推至一般人群存在问题。

要点

  • 透析液暴露的成人5期慢性肾病患者中,铝神经毒性者中位血铝467 µg/L(IQR 230-752),骨病者142 µg/L(IQR 46-309),无症状过载者35 µg/L(IQR 26-51),神经毒性者显著更高(p<0.0001)。
  • 口服氢氧化铝的成人中,铝神经毒性者中位血铝682 µg/L(IQR 438-770),骨病者100 µg/L(IQR 62-138),差异有统计学意义(p=0.007)。
  • 13例膀胱内铝暴露肿瘤患者全部发生铝神经毒性,中位血铝157 µg/L(IQR 45-276)。
  • 血浆置换相关:3例5期慢性肾病者发生铝骨病,中位血/血清铝73 µg/L(IQR 59-81);门诊血浆置换6例无症状过载者中位肌酐清除率71 mL/min(IQR 40-106)、中位血铝49 µg/L(IQR 34-116);ICU急性肾损伤7例无症状过载者中位血铝30 µg/L(IQR 17-35)(p=0.02)。
  • 饮用水暴露6例全部发生铝骨病,中位血铝17 µg/L(IQR 13-100)。

适用人群与场景

  • 有铝暴露个体数据的人类病例,暴露来源包括透析液、口服氢氧化铝、血浆置换、婴儿配方奶粉、膀胱内暴露和饮用水。
  • 透析液暴露者110例(成人99例、儿童11例);口服氢氧化铝20例(成人11例、儿童9例);血浆置换16例;婴儿配方奶粉14例;膀胱内暴露13例肿瘤患者;饮用水6例。

诊断标准与关键阈值

  • 铝神经毒性:脑功能改变和/或脑电图典型棘慢波波形。
  • 铝骨病:骨活检显示骨铝含量升高和骨形成减少。
  • 无症状铝过载:血铝升高但无神经毒性或骨病表现。

红旗征与不能漏的情况

  • 慢性肾病(尤其5期)患者长期透析液暴露或口服氢氧化铝,出现脑功能改变或脑电图棘慢波时需考虑铝神经毒性。
  • 膀胱内铝暴露后出现神经系统症状需警惕铝神经毒性。
  • 血浆置换患者出现骨病表现需考虑铝骨病。

研究设计与关键结果

  • 系统评价,检索1966年1月1日至2020年12月30日Embase、MEDLINE、PubMed和TOXNET,纳入37篇论文、179例铝暴露者。
  • 透析液暴露110例(成人99例、儿童11例):成人铝神经毒性50例中位血铝467 µg/L(IQR 230-752),铝骨病28例142 µg/L(IQR 46-309),无症状过载21例35 µg/L(IQR 26-51);神经毒性者显著高于骨病者(p<0.0001)和无症状过载者(p<0.0001)。
  • 口服氢氧化铝20例(成人11例、儿童9例):成人神经毒性8例中位血铝682 µg/L(IQR 438-770),骨病3例100 µg/L(IQR 62-138)(p=0.007);儿童神经毒性5例335 µg/L(IQR 229-601),骨病1例1030 µg/L,无症状过载3例98 µg/L(IQR 65-365)。
  • 血浆置换:3例5期慢性肾病发生铝骨病,中位血/血清铝73 µg/L(IQR 59-81);门诊血浆置换6例无症状过载者中位肌酐清除率71 mL/min(IQR 40-106)、中位血铝49 µg/L(IQR 34-116);ICU急性肾损伤7例无症状过载者中位血铝30 µg/L(IQR 17-35)(p=0.02)。
  • 膀胱内暴露13例全部发生铝神经毒性,中位血铝157 µg/L(IQR 45-276)。
  • 饮用水暴露6例全部发生铝骨病,中位血铝17 µg/L(IQR 13-100)。
  • 暴露来源中位持续时间:透析液48个月,口服氢氧化铝20个月,血浆置换2个月,婴儿配方奶粉最短2周,膀胱内暴露2天。

证据类型、等级与局限

  • 证据类型:系统评价,纳入37篇论文、179例个体数据。
  • 局限:数据来自肿瘤患者,将这些浓度外推至一般人群存在问题;不能排除铝神经毒性可在低于5期慢性肾病患者历史报告浓度时发生。

对床旁实践的改变

  • 对慢性肾病(尤其5期)长期透析或口服氢氧化铝者,出现脑功能改变或脑电图棘慢波时,即使血铝低于历史报告浓度也应考虑铝神经毒性。
  • 膀胱内铝暴露后需监测神经系统症状,该人群在较低血铝浓度(中位157 µg/L)即可发生神经毒性。
  • 血浆置换患者应关注铝骨病和铝过载,尤其5期慢性肾病及ICU急性肾损伤患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Aluminium exposure is associated with bone disease (an elevated bone content of aluminium and reduced bone formation on bone biopsy) and neurotoxicity (features of altered brain functions and/or typical spike and slow wave waveforms on electroencephalogram) in patients with elevated blood aluminium concentrations.

OBJECTIVES: To critically analyse the literature to determine the dose-toxicity relationships between aluminium exposure and related bone disease and aluminium neurotoxicity.

METHODS: A systematic review of the literature with collation and analysis of individual data of human cases of aluminium exposure was conducted between 1 January 1966 and 30 December 2020. Embase, MEDLINE (OVID MEDLINE), PubMed and TOXNET were searched with the following strategies: "Aluminium AND toxicity OR aluminium AND poisoning OR aluminium AND dialysis OR aluminium AND chronic renal failure OR aluminium AND intravenous" limited to "(human)". Inclusion criteria required individual data relating to aluminium exposure in humans. Papers in which features of aluminium toxicity and analytical confirmation of aluminium exposure could not be determined in individual patients were excluded.

RESULTS: Thirty-seven papers were identified, which included data on 179 individuals exposed to aluminium. The sources of aluminium exposure (median duration of exposure) were: dialysis fluid (48 months) in 110 cases; oral aluminium hydroxide (20 months) in 20 cases; plasma exchange (2 months) in 16 cases; infant formula feed (minimal duration of 2 weeks) in 14 cases; intravesical exposures (2 days) in 13 oncology patients and potable water exposure in six cases.

EXPOSURE TO DIALYSIS FLUID: Of the 110 patients exposed to dialysis fluid, 99 were adults and 11 children, who were analysed separated. Of the adults, 50 with aluminium neurotoxicity had a median aluminium concentration of 467 µg/L (IQR 230 - 752), 28 with aluminium bone disease had a median aluminium concentration of 142 µg/L (IQR 46-309) and 21 with asymptomatic aluminium overload had a median aluminium concentration of 35 µg/L (IQR 26-51). Median aluminium concentrations were significantly greater in patients with aluminium neurotoxicity compared to those with aluminium bone disease (p < 0.0001) or asymptomatic aluminium overload (p < 0.0001).

ORAL ALUMINIUM HYDROXIDE: Of the 20 cases, 11 were adults and nine were children. Of the 11 adults, eight with aluminium neurotoxicity had a median aluminium concentration of 682 µg/L (IQR 438-770) and three with aluminium bone disease had a median aluminium concentration of 100 µg/L (IQR 62-138) (p = 0.007). Of the nine children, five had aluminium neurotoxicity with a median aluminium concentration of 335 µg/L (IQR 229-601), one had aluminium bone disease and an aluminium concentration of 1030 µg/L and three had asymptomatic aluminium overload with a median aluminium concentration 98 µg/L (IQR 65-365).

PLASMA EXCHANGE: Three patients with stage 5 chronic kidney disease developed aluminium bone disease during plasma exchange; their median blood or serum aluminium concentration was 73 µg/L (IQR 59-81). Asymptomatic aluminium overload was reported in six patients receiving outpatient plasma exchange who had a median creatinine clearance of 71 mL/min (IQR 40-106) and a median aluminium concentration of 49 µg/L (IQR 34-116), and in seven intensive care patients with acute kidney injury whose median aluminium concentration was 30 µg/L (IQR 17-35); (p = 0.02).

INTRAVESICAL EXPOSURES: All 13 intravesical exposures developed aluminium neurotoxicity and had a median aluminium concentration of 157 µg/L (IQR 45-276).

POTABLE WATER: All six patients developed aluminium bone disease and their median blood aluminium concentration was 17 µg/L (IQR 13-100).

CONCLUSIONS: Toxic aluminium exposure can result in neurotoxicity and bone disease, especially in patients with chronic kidney disease. Adults with stage 5 chronic kidney disease chronically exposed to aluminium developed aluminium neurotoxicity at higher concentrations than those with aluminium bone disease or with asymptomatic aluminium overload. Aluminium neurotoxicity was reported at lower concentrations following acute exposure to intravesical aluminium. Extrapolating the relevance of these concentrations to the general population is problematic in that the data were derived from oncology patients, however, the possibility that aluminium neurotoxicity may occur at concentrations lower that those reported historically in patients with stage 5 chronic kidney disease cannot be excluded.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Coulson JM, Hughes BW. Dose-response relationships in aluminium toxicity in humans. Clin Toxicol (Phila). 2022. PMID: 35179097. doi:10.1080/15563650.2022.2029879

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。